A citation-based method for searching scientific literature

Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn, John M Lachin, Darren K McGuire, Michael J Pencina, Eberhard Standl, Peter P Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D Peterson, Rury R Holman. N Engl J Med 2015
Times Cited: 1525



Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Times Cited: 3053




List of shared articles



Times cited

Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2.
Francesco Maranta, Lorenzo Cianfanelli, Domenico Cianflone. Adv Exp Med Biol 2021
10


SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis.
Larry A Weinrauch, Jiankang Liu, Alissa R Segal, Jason Woodward, John A D'Elia. J Diabetes Complications 2021
1

Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Jessica M Franklin, Elisabetta Patorno, Rishi J Desai, Robert J Glynn, David Martin, Kenneth Quinto, Ajinkya Pawar, Lily G Bessette, Hemin Lee, Elizabeth M Garry,[...]. Circulation 2021
28

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li,[...]. Protein Cell 2021
6

Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia.
María Aguilar-Ballester, Gema Hurtado-Genovés, Alida Taberner-Cortés, Andrea Herrero-Cervera, Sergio Martínez-Hervás, Herminia González-Navarro. Int J Mol Sci 2021
4

A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro. Cardiovasc Diabetol 2021
7

Glucose-Lowering Medications and Cardiovascular Outcomes.
Madhan Shanmugasundaram, J R Exequiel Pineda, Sangeetha Murugapandian. Curr Cardiol Rep 2021
1

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku. Expert Opin Drug Saf 2021
0

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
1

Diabetes Management in Patients with Heart Failure.
Jia Shen, Barry H Greenberg. Diabetes Metab J 2021
0

Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
Tina K Thethi, Anika Bilal, Richard E Pratley. Curr Cardiol Rep 2021
1


Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy.
Lisa Dannenberg, Sarah Weske, Malte Kelm, Bodo Levkau, Amin Polzin. Pharmacol Ther 2021
1

CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.
Gianluigi Savarese, Javed Butler, Lars H Lund, Deepak L Bhatt, Stefan D Anker. Cardiovasc Res 2021
1

Role of diabetes in stroke: Recent advances in pathophysiology and clinical management.
Sian A Bradley, Kevin J Spring, Roy G Beran, Dimitrios Chatzis, Murray C Killingsworth, Sonu M M Bhaskar. Diabetes Metab Res Rev 2021
0

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno,[...]. Eur J Prev Cardiol 2021
0

JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure.
Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito,[...]. Circ J 2021
1

Glucose-lowering therapy in patients undergoing percutaneous coronary intervention.
Isabelle Johansson, Ilaria Dicembrini, Edoardo Mannucci, Francesco Cosentino. EuroIntervention 2021
0

JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure.
Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito,[...]. J Card Fail 2021
0

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management.
Antonio Ceriello, Doina Catrinoiu, Chanchal Chandramouli, Francesco Cosentino, Annique Cornelia Dombrowsky, Baruch Itzhak, Nebojsa Malić Lalic, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović,[...]. Cardiovasc Diabetol 2021
0

A Review of the Renoprotective Effects of Novel Antidiabetic Agents.
Kelsey M Leite, Allissa M Long, Marissa L Ostroff, Leanna Borges, Gregory Braden. J Pharm Pract 2021
1

Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.
Shun Kohsaka, Masayoshi Takeda, Johan Bodegård, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici. J Diabetes Investig 2021
1

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, Maria I Markou, Erifili E Hatziagelaki, Charalampos A Grassos, Maria L Velliou, John D Barbetseas. Am J Cardiovasc Drugs 2021
2

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Kåre I Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack,[...]. Diabetes Obes Metab 2021
13

Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study.
Mariarosaria De Luca, Giorgio Bosso, Antonio Valvano, Vincenzo Guardasole, Amodio Botta, Vincenzo Carbone, Giovanni Carella, Andrea Del Buono, Giuseppe Di Giovanni, Biagio Fimiani,[...]. Intern Emerg Med 2021
3

Changing Fields-Diabetes Medications Invading the Cardiovascular Space.
Lauren D Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P Shah, Brandon E Cave. Curr Probl Cardiol 2021
0

Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.
Christie A Schumacher, Elizabeth K Van Dril, Kayce M Shealy, Jennifer D Goldman. Clin Diabetes 2021
0

Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy.
Amit K Rai, Brooke Lee, Ramesh Gomez, Deepu Rajendran, Mahmood Khan, Venkata Naga Srikanth Garikipati. Front Physiol 2021
1


Use of diabetes medications in traditional Medicare and Medicare Advantage.
Bruce E Landon, Alan M Zaslavsky, Jeffrey Souza, John Z Ayanian. Am J Manag Care 2021
0

Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation.
Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Jiro Kondo, Hideyuki Inoue, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane. PLoS One 2021
1

Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
Qutuba G Karwi, Kim L Ho, Simran Pherwani, Ezra B Ketema, Qiu Yu Sun, Gary D Lopaschuk. Cardiovasc Res 2021
1


Role of newer antidiabetic drugs on cardiovascular prevention and heart failure.
Jesús Miguel Rojas-Velázquez, Alejandro Giralt-Herrera, Jessica Leiva-Enríquez, Jennifer Leiva-Enríquez. Clin Investig Arterioscler 2021
0

Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies.
Omar S Alkhezi, Haifa A Alsuhaibani, Amal A Alhadyab, Mashael E Alfaifi, Basmah Alomrani, Ali Aldossary, Osamah M Alfayez. Prim Care Diabetes 2021
0

Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type2 diabetes.
Ana Romero, Gemma Llauradó, José-Miguel González-Clemente. Endocrinol Diabetes Nutr (Engl Ed) 2021
0

Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies.
Angelo Avogaro, Francesco Barillà, Franco Cavalot, Agostino Consoli, Massimo Federici, Massimo Mancone, Stefania Paolillo, Roberto Pedrinelli, Gianluca Perseghin, Pasquale Perrone Filardi,[...]. Nutr Metab Cardiovasc Dis 2021
0

Recent advances in new-onset diabetes mellitus after kidney transplantation.
Tess Montada-Atin, G V Ramesh Prasad. World J Diabetes 2021
0

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Asako Sato, Edward A O'Neill, Samuel S Engel, Keith D Kaufman. Diabetes Obes Metab 2021
1

Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus.
Sharmaine Thirunavukarasu, Louise Ae Brown, Amrit Chowdhary, Nicholas Jex, Peter Swoboda, John P Greenwood, Sven Plein, Eylem Levelt. Diab Vasc Dis Res 2021
0


Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Adam J Nelson, Neha J Pagidipati, Vanita R Aroda, Matthew A Cavender, Jennifer B Green, Renato D Lopes, Hussein Al-Khalidi, Tanya Gaynor, Lisa A Kaltenbach, Julienne K Kirk,[...]. Circulation 2021
0